News | May 20, 2008

Drug Reduces Hospitalization in AF Patients

May 21, 2008 - Dronedarone significantly reduces the incidence of cardiovascular hospitalization or death in patients with atrial fibrillation (AF), according to results of the ATHENA Trial presented at Heart Rhythm 2008.

Dronedarone is a new antiarrhythmic compound being developed for the treatment of atrial fibrillation and atrial flutter. The ATHENA Trial is a placebo-controlled, double-blind, morbidity and mortality study designed to assess the efficacy of dronedarone for the prevention of cardiovascular hospitalization or death from any cause in patients with AF or atrial flutter.

“ATHENA is the first large trial of an antiarrhythmic agent that measures if an antiarrhythmic drug can reduce the composite outcome of the time to first cardiovascular hospitalization or death from any cause in an AF population,” stated the trial’s lead author, Stefan H. Hohnloser, MD, FHRS at J.W. Goethe University in Frankfurt, Germany. “The positive effects of dronedarone on the AF population are significant and extremely important to the field of cardiology.”

The trial randomized 4,628 patients with AF or atrial flutter, or with a history of the disorder to receive dronedarone or placebo with a minimum follow-up of one year. The primary study outcome was time to first cardiovascular hospitalization or death from any cause and secondary outcomes were total death, cardiovascular death and cardiovascular hospitalization.

The study findings included:

* 24.2 percent reduction in the risk of cardiovascular hospitalization or death from any cause during the study period, the study primary endpoint (p=0.001)
* 30 percent reduction in the risk of cardiovascular death (including sudden death) on top of standard therapy, including rate control drugs and antithrombotics, a pre-specified secondary endpoint (p=0.03)
* 25.5 percent reduction of first cardiovascular hospitalizations (p=0.001)
* A trend towards 16 percent less death from any cause (p=0.18)
* Lower mortality overall in the dronedarone arm compared to the placebo group at all times of the study

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init